May 9, 2023 10:58 AM EDTUpdated 11:23 AM

MarketingRx roundup: AbbVie debuts Vraylar campaign for depression; Amylyx re-ups “Get Inked” for ALS effort

Beth Snyder Bulik

Senior Editor

In December, AbbVie received a fourth indication for Vraylar as an add-on to antidepressants for the treatment of major depressive disorder – and now it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

MarketingRx roundup: AbbVie debuts Vraylar campaign for depression; Amylyx re-ups “Get Inked” for ALS effort

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Mar­ket­ingRx roundup: Ab­b­Vie de­buts Vray­lar cam­paign for de­pres­sion; Amy­lyx re-ups “Get Inked” for ALS ef­fort

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

MarketingRx roundup: AbbVie debuts Vraylar campaign for depression; Amylyx re-ups “Get Inked” for ALS effort